West Pharmaceutical Services (WST) financial statements

+192.5%since 2008
FY2025 revenue
$3.1B▲ +6.3%
FY2025 net income
$494M▲ +0.2%
FY2025 diluted EPS
$6.79▲ +1.5%
FY2025 free cash flow
$469M▲ +69.6%

West Pharmaceutical Services income statement

West Pharmaceutical Services income statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue3,0742,8932,950
Gross profit1,1049991,129
Operating income585570676
Pretax income601586698
Net income494493593
Diluted earnings per share6.796.697.88

West Pharmaceutical Services balance sheet

West Pharmaceutical Services balance sheet
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents791485854
Total assets4,2703,6433,830
Total liabilities1,094961949
Total equity3,1762,6822,881
Long-term debt20320373

West Pharmaceutical Services cash flow statement

West Pharmaceutical Services cash flow statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow755653777
Capital expenditure-286-377-362
Free cash flow (derived)469276415
Dividends paid-61-59-57
Share repurchases-134-561-438

Quarterly highlights

Quarterly highlights
USD millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)875872845805
Operating income (derived)267179177157
Net income (derived)214154139132
Diluted earnings per share3.022.151.92n/a
Operating cash flow (derived)19012490251
Total assets4,0614,0764,1104,270

West Pharmaceutical Services major shareholders

West Pharmaceutical Services major shareholders
HolderShare of classSharesFiled
Abigail P. Johnson8.5%5,962,7385 November 2026
FMR LLC8.5%5,962,7385 November 2026
BlackRock, Inc.8.4%6,066,85224 April 2025
Vanguard Capital Management7.5%5,397,79130 April 2026
Vanguard Portfolio Management5.7%4,102,67429 April 2026

West Pharmaceutical Services 10-K and SEC filings

West Pharmaceutical Services 10-K and SEC filings
FiledFormTypeDescription
29 October 202610-QQuarterly reportQuarterly report
29 October 20268-KCurrent reportCurrent report
26 October 20268-KCurrent reportCurrent report
23 July 202610-QQuarterly reportQuarterly report
23 July 20268-KCurrent reportCurrent report
14 July 20268-KCurrent reportCurrent report
1 June 20268-KCurrent reportCurrent report
11 May 20268-KCurrent reportCurrent report

Common questions

What was West Pharmaceutical Services' revenue in fiscal 2025?

West Pharmaceutical Services reported $3.1 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 6.3% from fiscal 2024.

What was West Pharmaceutical Services' net income in fiscal 2025?

West Pharmaceutical Services reported net income of $494 million for fiscal 2025, the year ended 31 December 2025, up 0.2% from fiscal 2024. Diluted earnings per share were $6.79.

What was West Pharmaceutical Services' free cash flow in fiscal 2025?

West Pharmaceutical Services had $469 million in free cash flow in fiscal 2025. Operating cash flow was $755 million and capital expenditure was $286 million.

What were West Pharmaceutical Services' total assets at the end of fiscal 2025?

West Pharmaceutical Services reported total assets of $4.3 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much West Pharmaceutical Services history does each plan include?

Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.